Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
Sponsor: National Taiwan University Hospital
Summary
The goal of this clinical trial is to learn if Cabergoline (Dostinex), a dopamine agonist which has been widely used to treat hyperprolactinemia, prolactinoma for many years, works to treat nonfunctioning pituitary adenoma (NFPA) in adults. The main questions it aims to answer are: Does cabergoline reduce the size of NFPA effectively when used as primary therapy? Participants will: Be 1:1 randomized into two groups. Either to take cabergoline or none for 48 weeks, Visit the clinic every 12 weeks for checkups and tests, Undergo scheduled imaging studies, Magnetic Resonance Imaging (MRI) to measure the change of tumor size.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-05-20
Completion Date
2028-12-31
Last Updated
2025-06-24
Healthy Volunteers
No
Conditions
Interventions
Cabergoline 0.5 MG
Cabergoline (Dostinex ®) 0.5 mg/tablet. Cabergoline will be given orally 1mg/week (Day1-14), 2mg/week (Day15-end of the study).
Locations (1)
National Taiwan University Hospital
Taipei, Taiwan, Taiwan